Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Overweight rating on Travere Therapeutics (NASDAQ:TVTX) and raised the price target from $14 to $18.
October 01, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has increased its price target for Travere Therapeutics from $14 to $18, maintaining an Overweight rating. This suggests confidence in the company's future performance.
The increase in price target from $14 to $18 by Barclays, along with maintaining an Overweight rating, indicates a positive outlook on Travere Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100